CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	103	104	106	283	303	378
Market Cap Growth	47.63%	-1.80%	-62.58%	-6.69%	-19.81%	-44.44%
Enterprise Value	-35	-58	-71	-6	7	105
PE Ratio	6.60	-182.48	-1.06	-2.44	-4.67	-2.84
PS Ratio	0.86	1.03	1.99	7.57	4.43	14.04
PB Ratio	-4.66	-2.19	-1.23	-615.53	-38.95	7.39
P/FCF Ratio	-1.60	-1.83	-0.94	-2.34	102.63	-2.62
P/OCF Ratio	-1.61	-1.85	-0.95	-2.37	57.57	-2.69
EV/Sales Ratio	0.08	-0.57	-1.33	-0.15	0.11	3.92
EV/EBITDA Ratio	0.35	-6.24	0.76	0.05	-0.10	-0.82
EV/EBIT Ratio	0.45	-17.34	0.71	0.05	-0.09	-0.79
EV/FCF Ratio	-0.10	1.01	0.63	0.05	2.51	-0.73
Debt / Equity Ratio	-0.41	-0.29	-0.21	-39.34	-2.79	0.49
Debt / EBITDA Ratio	0.49	1.51	-0.19	-0.16	-0.30	-0.19
Debt / FCF Ratio	-0.14	-0.25	-0.16	-0.15	7.35	-0.17
Quick Ratio	1.14	1.15	1.51	3.94	4.67	3.47
Current Ratio	1.16	1.17	1.55	3.99	4.76	3.54
Asset Turnover	0.58	0.47	0.20	0.10	0.17	0.07
Return on Equity (ROE)	-30.70%	0.80%	-666.30%	-119.40%	-153.50%	-148.70%
Return on Assets (ROA)	8.10%	-0.30%	-38.00%	-30.00%	-16.50%	-34.00%
Return on Capital (ROIC)	-46.48%	-3.32%	149.70%	-659.44%	-579.38%	-186.20%
Earnings Yield	16.07%	-0.55%	-93.93%	-41.01%	-21.41%	-35.18%
FCF Yield	-89.77%	-54.78%	-106.42%	-42.70%	0.97%	-38.13%
Buyback Yield / Dilution	-24.73%	-12.27%	-2.48%	-39.01%	-1.79%	-8.81%
Total Shareholder Return	-24.73%	-12.27%	-2.48%	-39.01%	-1.79%	-8.81%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).